ClinVar Miner

Submissions for variant NM_000276.4(OCRL):c.2389G>C (p.Ala797Pro)

dbSNP: rs935956958
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000687544 SCV000815117 pathogenic Lowe syndrome 2018-06-09 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change impairs binding to APPL1 and disrupts normal endosomal co-localization with EGFP (PMID: 17765681). In addition, experimental studies on fibroblasts from an individual carrying this missense change showed a reduced amount of OCRL protein and lower PI(4,5)P2-phosphatase activity (PMID: 21031565). This variant has been observed to be hemizygous in individuals affected with Lowe syndrome (PMIID: 10923037, 21031565). This variant is also known as p.Ala780Pro in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with proline at codon 797 of the OCRL protein (p.Ala797Pro). The alanine residue is highly conserved and there is a small physicochemical difference between alanine and proline.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.